Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluad and Fluad Quadrivalent efficacy study in adults aged 65 years and older
NL-OMON59133Phase 3Active, not recruiting
- Sponsor
- CSL Seqirus
- Start
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Fluzone Trivalent and influenza vaccine (surface antigen, inactivated, adjuvanted) in influenza (4 arms), sponsored by CSL Seqirus. Primary endpoint: First occurrence of RT-PCR-confirmed influenza due to any influenza A and/or B strain. Started Oct 2023; status: active, not recruiting.
02
Drugs
Fluzone Trivalentinfluenza vaccine (surface antigen, inactivated, adjuvanted)
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON59133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59133.